Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population

Aim: Proprotein convertase subtilisin/kexin type 9 (PCSK9) has been identified as an important regulator of low-density lipoprotein (LDL) receptor processing. Evolocumab and alirocumab are PCSK9 inhibitors; however, little is known about the association between PCSK9 levels and lipid profiles in a g...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamamura, Hitoshi, Adachi, Hisashi, Enomoto, Mika, Fukami, Ako, Nakamura, Sachiko, Nohara, Yume, Morikawa, Nagisa, Sakaue, Akiko, Toyomasu, Kenta, Yamamoto, Maki, Fukumoto, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japan Atherosclerosis Society 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8147011/
https://www.ncbi.nlm.nih.gov/pubmed/32624555
http://dx.doi.org/10.5551/jat.56390

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8147011/
https://www.ncbi.nlm.nih.gov/pubmed/32624555
http://dx.doi.org/10.5551/jat.56390

Ejemplares similares